Collectively, our data provide compelling evidence in vitro and in vivo that PRMT5 inhibitors could be used in combination clinically approved PARP inhibitors and chemotherapies for the treatment of ovarian or breast cancer, potentially irrespective of genomic HRD status. This evidence concerns the gene PRMT5 and breast carcinoma.